Robert Vigersky

Last updated

Robert A. Vigersky is an American endocrinologist, Professor of Medicine at the Uniformed Services University of the Health Sciences, and pioneering military healthcare professional. [1] [2] His career has focused on diabetes care, research, and advocacy, publishing 148 papers [3] and 118 abstracts in the fields of reproductive endocrinology and diabetes. [3] [4] Vigersky is a retired colonel in the U.S. Army Medical Corps, [5] [2] [6] past president of the Endocrine Society, [7] [4] and recipient of the General Maxwell R. Thurman Award. He served in Iraq, Korea and Germany and is the recipient of military awards including the U.S. Army's Legion of Merit in 2009. [8]

Contents

Professional experience and research

Vigersky is a graduate of the 6-year Program in Liberal Arts and Medicine of Boston University, the Internal Medicine Residency at The Johns Hopkins Hospital, [9] and the Endocrine Fellowship at National Institutes of Health. [10] Upon completing his fellowship, Dr. Vigersky joined Walter Reed Army Medical Center, where he became Assistant Chief of Endocrinology until he left the military in 1984. [10] After leaving the military, Dr. Vigersky entered the private practice, where he became the President of the Endocrine and Diabetes Group of Washington, and served as medical director of the Diabetes Treatment Center at Georgetown University Hospital and the Washington Hospital Center.

In 2000, Dr. Vigersky re-entered the Army, establishing the Diabetes Institute [11] at the Walter Reed Health Care System, where he was the medical director and where his research focused on the use of technology [5] and decision-support systems to improve outcomes for patients with diabetes. [12] He is the current Chief Medical Officer of Medtronic Diabetes. [10]

Selected publications

Related Research Articles

<span class="mw-page-title-main">Glucose tolerance test</span> Medical test of how quickly glucose is cleared from the blood

The glucose tolerance test is a medical test in which glucose is given and blood samples taken afterward to determine how quickly it is cleared from the blood. The test is usually used to test for diabetes, insulin resistance, impaired beta cell function, and sometimes reactive hypoglycemia and acromegaly, or rarer disorders of carbohydrate metabolism. In the most commonly performed version of the test, an oral glucose tolerance test (OGTT), a standard dose of glucose is ingested by mouth and blood levels are checked two hours later. Many variations of the GTT have been devised over the years for various purposes, with different standard doses of glucose, different routes of administration, different intervals and durations of sampling, and various substances measured in addition to blood glucose.

<span class="mw-page-title-main">Hyperglycemia</span> Too much blood sugar, usually because of diabetes

Hyperglycemia is a condition in which an excessive amount of glucose circulates in the blood plasma. This is generally a blood sugar level higher than 11.1 mmol/L (200 mg/dL), but symptoms may not start to become noticeable until even higher values such as 13.9–16.7 mmol/L (~250–300 mg/dL). A subject with a consistent range between ~5.6 and ~7 mmol/L is considered slightly hyperglycemic, and above 7 mmol/L is generally held to have diabetes. For diabetics, glucose levels that are considered to be too hyperglycemic can vary from person to person, mainly due to the person's renal threshold of glucose and overall glucose tolerance. On average, however, chronic levels above 10–12 mmol/L (180–216 mg/dL) can produce noticeable organ damage over time.

<span class="mw-page-title-main">Type 2 diabetes</span> Type of diabetes mellitus with high blood sugar and insulin resistance

Type 2 diabetes, formerly known as adult-onset diabetes, is a form of diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent urination, and unexplained weight loss. Symptoms may also include increased hunger, feeling tired, and sores (wounds) that do not heal. Often symptoms come on slowly. Long-term complications from high blood sugar include heart disease, strokes, diabetic retinopathy which can result in blindness, kidney failure, and poor blood flow in the limbs which may lead to amputations. The sudden onset of hyperosmolar hyperglycemic state may occur; however, ketoacidosis is uncommon.

<span class="mw-page-title-main">Resistin</span> Mammalian protein found in Homo sapiens

Resistin also known as adipose tissue-specific secretory factor (ADSF) or C/EBP-epsilon-regulated myeloid-specific secreted cysteine-rich protein (XCP1) is a cysteine-rich peptide hormone derived from adipose tissue that in humans is encoded by the RETN gene.

<span class="mw-page-title-main">Obestatin</span> Hormone that is produced in the stomach

Obestatin is a hormone that is produced in specialized epithelial cells of the stomach and small intestine of several animals including humans. Obestatin was originally identified as an anorectic peptide, but its effect on food intake remains controversial.

<span class="mw-page-title-main">Prediabetes</span> Predisease state of hyperglycemia with high risk for diabetes

Prediabetes is a component of the metabolic syndrome and is characterized by elevated blood sugar levels that fall below the threshold to diagnose diabetes mellitus. It usually does not cause symptoms but people with prediabetes often have obesity, dyslipidemia with high triglycerides and/or low HDL cholesterol, and hypertension. It is also associated with increased risk for cardiovascular disease (CVD). Prediabetes is more accurately considered an early stage of diabetes as health complications associated with type 2 diabetes often occur before the diagnosis of diabetes.

<span class="mw-page-title-main">CAPN10</span> Protein-coding gene in the species Homo sapiens

Calpain-10 is a protein that in humans is encoded by the CAPN10 gene.

<span class="mw-page-title-main">Diabetic cardiomyopathy</span> Medical condition

Diabetic cardiomyopathy is a disorder of the heart muscle in people with diabetes. It can lead to inability of the heart to circulate blood through the body effectively, a state known as heart failure(HF), with accumulation of fluid in the lungs or legs. Most heart failure in people with diabetes results from coronary artery disease, and diabetic cardiomyopathy is only said to exist if there is no coronary artery disease to explain the heart muscle disorder.

<span class="mw-page-title-main">Minimed Paradigm</span> Insulin pumps

MiniMed Paradigm is a series of insulin pumps manufactured by Medtronic for patients with diabetes mellitus. The pump operates with a single AA battery and uses a piston-plunger pump to infuse a programmed amount of insulin into the patient through a length of tubing. The Paradigm uses a one-way wireless radio frequency link to receive blood sugar measurements from select glucose meters. The Paradigm RT series adds the ability to receive data from a mated continuous blood-glucose monitor. Although the pump can use these measurements to assist in calculating a dose of insulin, no actual change in insulin delivery occurs without manual user-intervention.

<span class="mw-page-title-main">1,5-Anhydroglucitol</span> Chemical compound

1,5-Anhydroglucitol, also known as 1,5-AG, is a naturally occurring monosaccharide found in nearly all foods. Blood concentrations of 1,5-anhydroglucitol decrease during times of hyperglycemia above 180 mg/dL, and return to normal levels after approximately 2 weeks in the absence of hyperglycemia. As a result, it can be used for people with either type-1 or type-2 diabetes mellitus to identify glycemic variability or a history of high blood glucose even if current glycemic measurements such as hemoglobin A1c (HbA1c) and blood glucose monitoring have near normal values. Despite this possible use and its approval by the FDA, 1,5-AG tests are rarely ordered. There is some data suggesting that 1,5-AG values are useful to fill the gap and offer complementary information to HbA1c and fructosamine tests.

Derek LeRoith, M.D., Ph.D is an endocrinologist and Professor of Medicine and the current Chief of the Hilda and J. Lester Gabrilove, M.D. Division of Endocrinology, Diabetes and Bone Disease and Director of the Metabolism Institute of the Mount Sinai Medical Center in New York City. He is an international expert in insulin-like growth factor-1 (IGF-1).

Cyril Y. Bowers, M.D., Emeritus Professor of Medicine at Tulane University School of Medicine, attended medical school at the University of Oregon and did an internship at the University of Washington. He then studied biochemistry at Cornell University and attended the Postgraduate School of Medicine at the University of Pennsylvania. From 1961-2004 he was the director of the Section of Endocrinology & Metabolism in the Department of Medicine at Tulane University School of Medicine. Dr. Bowers has served on the editorial board of several endocrine journals, was a member of the National Institute of Diabetes and Digestive and Kidney Diseases Study Section for eight years and has written over 400 articles in peer reviewed journals including chapters in books and over 200 abstracts.

Transgender hormone therapy, also called hormone replacement therapy (HRT) or gender-affirming hormone therapy (GAHT), is a form of hormone therapy in which sex hormones and other hormonal medications are administered to transgender or gender nonconforming individuals for the purpose of more closely aligning their secondary sexual characteristics with their gender identity. This form of hormone therapy is given as one of two types, based on whether the goal of treatment is masculinization or feminization:

Empagliflozin, sold under the brand name Jardiance among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes. It is not recommended for type 1 diabetes. It is taken by mouth.

<span class="mw-page-title-main">Leonid Poretsky</span>

Leonid Poretsky is a Russian-born American endocrinologist. His research interests include mechanisms of insulin action in the ovary, endocrinological aspects of AIDS, and clinical outcomes in diabetes. He has authored over 100 publications and has served on the National Institutes of Health's review committees and on the editorial boards of the Journal of Clinical Endocrinology and Metabolism and other endocrine journals.

<span class="mw-page-title-main">Dulaglutide</span> Diabetes medication

Dulaglutide, sold under the brand name Trulicity among others, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. It is a once-weekly injection.

Donald Lynn Loriaux is a Professor and Chief of Endocrinology and Diabetes at Oregon Health Sciences University. He is the inventor of the Lx Stethoscope, which increased variable frequency sound transfer, and has won various awards.

Ravinder Goswami is an Indian endocrinologist and professor at the department of endocrinology and metabolism at the All India Institute of Medical Sciences, Delhi. Known for his research on vitamin D deficiency, Goswami is an elected fellow of National Academy of Sciences, India and Indian Academy of Sciences. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards for his contributions to Medical Sciences in 2008.

Insulin autoimmune syndrome (IAS), a rare cause of reversible autoimmune hypoglycemia also known as Hirata's disease, was first described by Hirata in Japan in 1970.

Anne Peters is a endocrinologist, diabetes expert, and professor of clinical medicine at the Keck School of Medicine of USC. She runs diabetes centers in well-served Beverly Hills and under-resourced East Los Angeles. She teaches physicians and people with diabetes around the world how to better treat the condition, through lifestyle, medications and technology.

References

  1. ↑ Brigade, U.S. Army Medical Recruiting. "Head of Military Diabetes Institute Hopes to Put Breaks on Growing Epidemic". www.prnewswire.com. Retrieved 2017-09-04.
  2. 1 2 "Commendations & Commencements". NIH NIDDK. National Institute of Diabetes and Digestive and Kidney Diseases, Health Information Center. Retrieved 2017-09-04.
  3. 1 2 "Dr. Robert Vigersky, MD – Bethesda, MD | Endocrinology on Doximity". Doximity. Retrieved 2017-09-04.
  4. 1 2 "The Endocrine Society 2007 Laureate Awards". Endocrinology. 148 (8): 4104–4115. 2007-08-01. doi: 10.1210/endo.148.8.3451 . ISSN   0013-7227.
  5. 1 2 "Speaker Spotlight: Col. Robert Vigersky, MD - American Association of Diabetes Educators". www.aademeeting.org. Retrieved 2017-09-04.
  6. ↑ Special Operations Forces Medical Handbook. Government Printing Office. ISBN   9780160867194.
  7. ↑ "New Anti-Aging Stress Relievers". Harper's BAZAAR. 2014-09-03. Retrieved 2017-09-04.
  8. ↑ "Eleventh Annual Summit on Health Disparities/CBC Health Braintrust Meeting & Awards Dinner" (PDF). www.nmqf.org. National Minority Quality Forum. April 2014.
  9. ↑ "Dr. Robert Vigersky MD". USNews.com. Retrieved 2017-09-04.
  10. 1 2 3 "Dr. Robert Vigersky | Director of Clinical and Medical Affairs, Medtronic Diabetes". www.medtronicdiabetes.com. Retrieved 2017-09-04.
  11. ↑ "Diabetes Institute - Walter Reed National Military Medical Center". www.wrnmmc.capmed.mil. Walter Reed National Military Medical Center. Retrieved 2017-09-04.
  12. ↑ "Robert Alan Vigersky, MD". endo.confex.com. Retrieved 2017-09-04.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.